Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

NCT02630693 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

180

Enrollment

NETWORK

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Palbociclib 100mg
DRUG: Palbociclib 125mg
DRUG: Fulvestrant or Tamoxifen or Aromatase Inhibitor

Sponsor

Canadian Cancer Trials Group

Collaborators

[object Object]